<DOC>
	<DOCNO>NCT00238238</DOCNO>
	<brief_summary>Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Biological therapy , lenalidomide , may stimulate immune system different way stop cancer cell grow . Lenalidomide may also stop growth non-Hodgkin 's lymphoma blocking blood flow cancer . Giving rituximab together lenalidomide may kill cancer cell . This randomized phase II trial study well rituximab and/or lenalidomide work treat patient follicular non-Hodgkin 's lymphoma refractory rituximab .</brief_summary>
	<brief_title>Rituximab and/or Lenalidomide Treating Patients With Follicular Non-Hodgkin 's Lymphoma That Not Refractory Rituximab</brief_title>
	<detailed_description>Outline : This randomize , multicenter study . Patients randomize 1 3 treatment arm . Please see `` Arms '' section description treatment arm . The primary secondary objective study provide . Primary Objectives : - To determine response rate ( overall complete ) lenalidomide therapy rituximab + lenalidomide follicular NHL patient relapse . - To determine time progression lenalidomide therapy rituximab lenalidomide follicular NHL patient relapse . Secondary Objectives : - To compare time progression previous rituximab regimen obtain subsequently lenalidomide therapy rituximab + lenalidomide . - To determine toxicity profile lenalidomide therapy rituximab lenalidomide follicular NHL patient receive previous rituximab regimen . - To correlate Fc receptor polymorphism profile response lenalidomide rituximab + lenalidomide previously treat patient follicular NHL relapse . - To evaluate change Natural Killer ( NK ) cell , activate NK cell , activate T-cells several plasma cytokine follow rituximab therapy correlation observe change objective response rate . After completion study treatment , patient follow 10 year study entry .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Documentation Disease Previously treat , histologically confirm follicle center cell lymphoma , World Health Organization ( WHO ) classification , grade 1 , 2 , 3a Institutional flow cytometry immunohistochemistry must confirm Cluster Differentiation 20 ( CD20 ) antigen expression . Prior Treatment Patient must treat rituximab either alone combination chemotherapy . Patient must time progression ≥ 6 month last rituximab dose . No corticosteroid within two week prior study , except maintenance therapy nonmalignant disease . Maintenance therapy dose may exceed 20 mg/day prednisone equivalent . No prior radioimmunotherapy within 12 month study entry . Age ≥ 18 year . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 . Measurable disease must present either physical examination image study . Nonmeasurable disease alone acceptable . Any tumor mass &gt; 1 cm acceptable.Lesions consider nonmeasurable include follow : Bone lesion Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Bone marrow No known Central Nervous System ( CNS ) involvement lymphoma . No known Human Immunodeficiency Virus ( HIV ) infection . Nonpregnant nonnursing . Patients `` currently active '' second malignancy , nonmelanoma skin cancer , eligible . Patients recent history ( within 3 month study entry ) Deep Vein Thrombosis/Pulmonary Embolism ( DVT/PE ) eligible . Required Initial Laboratory Values : Absolute Neutrophil Count ( ANC ) ≥ 1000/µL Platelet count ≥ 75,000/µL Creatinine &lt; 1.5 x Upper Limit Normal ( ULN ) unless attribute lymphoma calculate clearance &gt; 50 mL/min ( patient dialysis eligible ) Total Bilirubin ≤ 2 x ULN unless attribute lymphoma Gilbert 's disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>